Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ORIC
ORIC
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ORIC News
Oncolytics Biotech Accelerates Cancer Treatment with New Executive Appointments
Jan 14 2026
Newsfilter
Oncolytics Biotech Accelerates Cancer Treatment Progress, Aiming for FDA Approval in 2026
Jan 14 2026
PRnewswire
ORIC Pharmaceuticals to Present Drug Developments at 44th J.P. Morgan Healthcare Conference
Jan 06 2026
Globenewswire
ORIC Pharmaceuticals (ORIC) Rises Following Promising ESMO Asia Data for Enozertinib, Leading Wells Fargo to Increase Valuation
Dec 16 2025
Yahoo Finance
ORIC Pharmaceuticals Reports Enozerinib Clinical Data with 67% Response Rate in 1L Patients
Dec 06 2025
Globenewswire
ORIC Pharmaceuticals Reports 67% ORR in 1L Patients for Enozerinib at ESMO Asia 2025
Dec 06 2025
Newsfilter
ORIC Pharmaceuticals Grants 69,200 Stock Options to New Employees
Dec 05 2025
Globenewswire
ORIC Pharmaceuticals Reports 35% ORR in Enozertinib Phase 1b Trial for NSCLC
Dec 05 2025
Globenewswire
ORIC Pharmaceuticals Reports 35% ORR in HER2 Mutation Patients from Enozertinib Trial
Dec 05 2025
Newsfilter
ORIC Pharmaceuticals Reports 80% ORR in 1L EGFR PACC Patients
Dec 05 2025
Globenewswire
ORIC Pharmaceuticals to Present Enozertinib Data at ESMO Asia Congress 2025
Dec 03 2025
Newsfilter
Three Health Care Stocks Poised for Significant Gains This December
Dec 03 2025
Benzinga
Helmerich and Payne Analyst Changes Stance; Check Out the Top 3 Upgrades for Friday
Nov 21 2025
Benzinga
IBM Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Friday
Nov 21 2025
Benzinga
Nasdaq Analyst Becomes Optimistic; Check Out the Top 5 Upgrades for Thursday
Nov 20 2025
Benzinga
Bellring Brands Analyst Changes Stance; Check Out Thursday's Top 3 Downgrades
Nov 20 2025
Benzinga
Show More News
